10x Genomics (TXG) Tops Q1 EPS by 19c, provides guidance

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.28), $0.19 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $154.9 million versus the consensus estimate of $132.58 million.

GUIDANCE:

10x Genomics sees Q2 2025 revenue of $138-142 million, versus the consensus of $145.3 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• Largo wins $125M U.S. defense contract for vanadium pentoxide supply
• Tessenderlo Group to take 20% stake in FMC for $400 million